PortalPublikationenCNS progression during vinblastine or targeted therapies for...

CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma

Standard

CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma : A case series. / Ruf, Stephanie; Hebart, Holger; Hjalgrim, Lisa Lyngsie; Kabickova, Edita; Lang, Peter; Steinbach, Daniel; Schwabe, Georg C; Woessmann, Wilhelm.

in: PEDIATR BLOOD CANCER, Jahrgang 65, Nr. 6, 06.2018, S. e27003.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Ruf, S, Hebart, H, Hjalgrim, LL, Kabickova, E, Lang, P, Steinbach, D, Schwabe, GC & Woessmann, W 2018, 'CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series', PEDIATR BLOOD CANCER, Jg. 65, Nr. 6, S. e27003. https://doi.org/10.1002/pbc.27003

APA

Ruf, S., Hebart, H., Hjalgrim, L. L., Kabickova, E., Lang, P., Steinbach, D., Schwabe, G. C., & Woessmann, W. (2018). CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series. PEDIATR BLOOD CANCER, 65(6), e27003. https://doi.org/10.1002/pbc.27003

Vancouver

Ruf S, Hebart H, Hjalgrim LL, Kabickova E, Lang P, Steinbach D et al. CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series. PEDIATR BLOOD CANCER. 2018 Jun;65(6):e27003. https://doi.org/10.1002/pbc.27003

Bibtex

@article{ba2924273e814508befa36beec90d0aa,
title = "CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series",
abstract = "Vinblastine and targeted therapies induce remissions in patients with relapsed or progressive anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). Central nervous system (CNS) prophylaxis often is not included during re-induction in CNS-negative relapse patients. We report on five patients with progressive or early relapsed ALK-positive ALCL who developed CNS progression during re-induction with vinblastine, crizotinib, or brentuximab vedotin given for bridging to allogeneic blood stem cell transplantation. These observations suggest that CNS prophylaxis should be considered in ALCL patients suffering progression during initial therapy who receive re-induction using agents with limited CNS penetration.",
keywords = "Journal Article",
author = "Stephanie Ruf and Holger Hebart and Hjalgrim, {Lisa Lyngsie} and Edita Kabickova and Peter Lang and Daniel Steinbach and Schwabe, {Georg C} and Wilhelm Woessmann",
note = "{\textcopyright} 2018 Wiley Periodicals, Inc.",
year = "2018",
month = jun,
doi = "10.1002/pbc.27003",
language = "English",
volume = "65",
pages = "e27003",
journal = "PEDIATR BLOOD CANCER",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

RIS

TY - JOUR

T1 - CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma

T2 - A case series

AU - Ruf, Stephanie

AU - Hebart, Holger

AU - Hjalgrim, Lisa Lyngsie

AU - Kabickova, Edita

AU - Lang, Peter

AU - Steinbach, Daniel

AU - Schwabe, Georg C

AU - Woessmann, Wilhelm

N1 - © 2018 Wiley Periodicals, Inc.

PY - 2018/6

Y1 - 2018/6

N2 - Vinblastine and targeted therapies induce remissions in patients with relapsed or progressive anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). Central nervous system (CNS) prophylaxis often is not included during re-induction in CNS-negative relapse patients. We report on five patients with progressive or early relapsed ALK-positive ALCL who developed CNS progression during re-induction with vinblastine, crizotinib, or brentuximab vedotin given for bridging to allogeneic blood stem cell transplantation. These observations suggest that CNS prophylaxis should be considered in ALCL patients suffering progression during initial therapy who receive re-induction using agents with limited CNS penetration.

AB - Vinblastine and targeted therapies induce remissions in patients with relapsed or progressive anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). Central nervous system (CNS) prophylaxis often is not included during re-induction in CNS-negative relapse patients. We report on five patients with progressive or early relapsed ALK-positive ALCL who developed CNS progression during re-induction with vinblastine, crizotinib, or brentuximab vedotin given for bridging to allogeneic blood stem cell transplantation. These observations suggest that CNS prophylaxis should be considered in ALCL patients suffering progression during initial therapy who receive re-induction using agents with limited CNS penetration.

KW - Journal Article

U2 - 10.1002/pbc.27003

DO - 10.1002/pbc.27003

M3 - SCORING: Journal article

C2 - 29512859

VL - 65

SP - e27003

JO - PEDIATR BLOOD CANCER

JF - PEDIATR BLOOD CANCER

SN - 1545-5009

IS - 6

ER -